Steven Bulera, Corporate Vice President, Chief Scientific Officer: Safety Assessment, Charles River Laboratories, explores various use-cases of AI in improving drug discovery. It’s difficult, if not impossible, to escape the headlines and reports detailing the extent to which the biomedical research industry is investing in artificial intelligence (AI). A November 2025 update by McKinsey & Company […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!